Arrowhead Pharmaceuticals, Inc. SEC filings ARWR
Arrowhead Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Apr 30, 2010. Its latest annual report, Form ARS, was filed on Jan 27, 2026 for the period ended Jan 26, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (material agreement, new debt). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 305B2 | Filing | Jan 8, 2026 | — |
| UPLOAD | Letter from the SEC | May 19, 2023 | — |
| CORRESP | Letter to the SEC | Apr 18, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2023 | — |
| CORRESP | Letter to the SEC | Mar 3, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 10, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2021 | — |
| CORRESP | Letter to the SEC | Feb 5, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2021 | — |
| CT ORDER | Filing | Mar 18, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2018 | — |
| CORRESP | Letter to the SEC | Mar 13, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2018 | — |
| 8-A12B | Filing | Mar 23, 2017 | — |
| EFFECT | Filing | Feb 3, 2017 | — |
| EFFECT | Filing | Feb 3, 2017 | — |
| CORRESP | Letter to the SEC | Feb 1, 2017 | — |
| CORRESP | Letter to the SEC | Feb 1, 2017 | — |
| CORRESP | Letter to the SEC | Jan 19, 2017 | — |
| CORRESP | Letter to the SEC | Jan 19, 2017 | — |
| CT ORDER | Filing | Jan 18, 2017 | — |
| CORRESP | Letter to the SEC | Jan 13, 2017 | — |
| CORRESP | Letter to the SEC | Jan 13, 2017 | — |
| CORRESP | Letter to the SEC | Nov 23, 2016 | — |
| CORRESP | Letter to the SEC | Nov 23, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2016 | — |
| EFFECT | Filing | Sep 22, 2016 | — |
| CORRESP | Letter to the SEC | Sep 20, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2016 | — |
| 8-A12G/A | Amendment no. 2 to form 8-a | Apr 7, 2016 | — |
| CT ORDER | Filing | Jul 21, 2015 | — |
| EFFECT | Filing | May 4, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2015 | — |
| CORRESP | Letter to the SEC | Apr 30, 2015 | — |
| CORRESP | Letter to the SEC | Apr 22, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2015 | — |
| CORRESP | Letter to the SEC | Mar 30, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 24, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2015 | — |
| CT ORDER | Filing | Sep 17, 2014 | — |
| EFFECT | Filing | Feb 12, 2014 | — |
| CORRESP | Letter to the SEC | Feb 11, 2014 | — |
| UPLOAD | Letter from the SEC | Feb 10, 2014 | — |
| EFFECT | Filing | Nov 5, 2013 | — |
| D | Filing | Oct 22, 2013 | — |
| EFFECT | Filing | May 29, 2013 | — |
| D | Filing | May 16, 2013 | — |
| CT ORDER | Filing | May 30, 2012 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2012 | — |
| CORRESP | Letter to the SEC | Mar 30, 2012 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2012 | — |
| EFFECT | Filing | Feb 22, 2012 | — |
| EFFECT | Filing | Feb 22, 2012 | — |
| EFFECT | Filing | Jan 30, 2012 | — |
| CORRESP | Letter to the SEC | Jan 26, 2012 | — |
| CORRESP | Letter to the SEC | Jan 13, 2012 | — |
| EFFECT | Filing | Jan 10, 2012 | — |
| EFFECT | Filing | Jan 10, 2012 | — |
| CORRESP | Letter to the SEC | Jan 9, 2012 | — |
| CORRESP | Letter to the SEC | Jan 9, 2012 | — |
| CORRESP | Letter to the SEC | Jan 9, 2012 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2011 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2011 | — |
| EFFECT | Filing | Aug 17, 2011 | — |
| CT ORDER | Filing | Mar 22, 2011 | — |
| 8-A12G/A | Amendment no.1 to form 8-a12b | Nov 1, 2010 | — |
| D | Filing | Sep 30, 2010 | — |
| EFFECT | Filing | Jun 11, 2010 | — |
| EFFECT | Filing | Jun 11, 2010 | — |
| EFFECT | Filing | Jun 11, 2010 | — |
Showing 71 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARWR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879407
- Former names
- ARROWHEAD RESEARCH CORP (until Apr 6, 2016); INTERACTIVE GROUP INC (until Jan 9, 2004); INTERACTIVE INC (until Feb 13, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.